Abstract
AbstractBackgroundNumerous studies on Alzheimer’s disease (AD) are being undertaken, and there is a plethora of high‐quality clinical data and resources for AD in Korea. However, because the resources and data are not thoroughly standardized, they are challenging to use. The Trial Ready Registry (TRR) and Dementia Platform Korea (DPK) technologies were developed to investigate possible AD therapy targets and biomarkers, as well as to progress the AD research field in Korea by standardizing the dementia dataset in Korea.MethodTo collect human‐derived materials with MCD, we designed the minimum common dataset (MCD), which includes clinical evaluations, cognitive evaluations, magnetic resonance imaging (MRI), Florbetaben (FBB)‐PET, Flutematamol (FMM)‐PET, and blood tests.ResultThe TRR‐DPK system is planned to enroll 3,000 participants in MCD exams, blood tests, and brain imaging by 2028. Since 2020, 942 people had been recruited for the system as of December 2022. We collected human‐derived materials such as plasma, serum, DNA, and PBMCs from participants with the purpose of distributing human‐derived materials matched to their brain imaging and clinical data.ConclusionWe expect that the TRR‐DPK system will improve AD research by giving researchers access to human‐derived materials and a variety of quality‐controlled data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
